for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pharming Group N.V.

PHAR.AS

Latest Trade

1.33EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.71

 - 

1.64

As of on the Euronext Amsterdam Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1.33
Open
--
Volume
--
3M AVG Volume
372.88
Today's High
--
Today's Low
--
52 Week High
1.64
52 Week Low
0.71
Shares Out (MIL)
634.99
Market Cap (MIL)
838.09
Forward P/E
16.91
Dividend (Yield %)
--

Next Event

Pharming Group NV at Jefferies Healthcare Conference (Virtual)

Latest Developments

More

Pharming Group Q1 Operating Profit Up At 19.4 Million Euros

Pharming Group: EC Approves Ruconest For Treatment Of HAE Attacks In Children

Pharming Enters Euronext Amsterdam Midkap Index

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pharming Group N.V.

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies. The Company’s products are aimed at treatments for genetic disorders and surgical and traumatic bleeding. Pharming’s technologies include novel transgenic platforms for the production of biopharmaceuticals, as well as technology and processes for the purification and formulation of these biopharmaceuticals. The Company’s commercial partners are: Santarus, Sobi, MegaPharm, Eczacibasi, Transmedic and Hyupjin. The Company operates worldwide. In March 2014, it announced downsizing of the Dutch operations following from strategic re-emphasis on collaborative development efforts and out-sourcing of non-core activities.

Industry

Biotechnology & Drugs

Contact Info

Darwinweg 24

2333 CR

Netherlands

+31.71.5247400

https://www.pharming.com/

Executive Leadership

Paul Jai Sekhri

Chairman of the Board of Supervisory Directors

Sijmen de Vries

Chairman of the Management Board, Chief Executive Officer

Juergen H. L. Ernst

Vice Chairman of the Board of Supervisory Directors

Robin Wright

Chief Financial Officer, Member of the Management Board

Stephen Toor

Senior Vice President and General Manager Pharming Americas, Member of the Management Board

Key Stats

2.17 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

0.1K

2018

0.1K

2019

0.2K

2020(E)

0.2K
EPS (EUR)

2017

-0.160

2018

0.040

2019

0.054

2020(E)

0.079
Price To Earnings (TTM)
25.06
Price To Sales (TTM)
4.58
Price To Book (MRQ)
7.32
Price To Cash Flow (TTM)
19.31
Total Debt To Equity (MRQ)
110.07
LT Debt To Equity (MRQ)
108.65
Return on Investment (TTM)
19.09
Return on Equity (TTM)
15.05

Latest News

Latest News

BRIEF-Pharming Group Q1 Operating Profit Up At 19.4 Million Euros

* PHARMING GROUP REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2020

BRIEF-Pharming Group: EC Approves Ruconest For Treatment Of HAE Attacks In Children

* RECEIVES EUROPEAN COMMISSION APPROVAL FOR TREATMENT OF ACUTE HEREDITARY ANGIOEDEMA ATTACKS IN CHILDREN WITH RUCONEST

BRIEF-Pharming Enters Euronext Amsterdam Midkap Index

* DESPITE UNCERTAINTY AROUND COVID-19, FOR NOW, WE DO NOT ANTICIPATE ANY ISSUES WITH REGARDS TO CONTINUOUS SUPPLY OF RUCONEST AND WE REMAIN CONFIDENT IN LONG-TERM PROSPECTS OF BUSINESS Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Pharming CFO Robin Wright To Step Down

* ROBIN WRIGHT, HAS DECIDED (FOR FAMILY REASONS) NOT TO PUT HIMSELF UP FOR RE-ELECTION AS A MEMBER OF BOARD OF MANAGEMENT AND THUS AS CHIEF FINANCIAL OFFICER

BRIEF-Pharming Group Receives FDA Approval Of New Facility For Expansion Of Ruconest® Production

* PHARMING GROUP NV SAYS RECEIVES FDA APPROVAL OF NEW FACILITY FOR EXPANSION OF RUCONEST® PRODUCTION

BRIEF-Pharming Group FY Net Profits Up At 36.2 Million Euros

* FULL YEAR NET PROFITS WERE EUR 36.2 MILLION ($40.5 MILLION), AN INCREASE OF 45% ON 2018

BRIEF-Pharming Enters Euronext Amsterdam SmallCap-Index (AScX)

* PHARMING ENTERS THE EURONEXT AMSTERDAM SMALLCAP-INDEX (ASCX) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Pharming Group Q4 Revenues From Product Sales OF EUR 32.7 Mln, Up 26 Pct Vs. Q3

* DELIVERED REVENUE FOR FULL YEAR OF EUR 89.6 MILLION (US$101.2 MILLION) - AN INCREASE OF 464% ON 2016

BRIEF-Pharming Announces FDA Acceptance For Review Of Supplemental Biologics License Application

* PHARMING ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS

BRIEF-Pharming Group Announces Further Conversion Of Ordinary Convertible Bonds

* BONDHOLDERS CONVERT €7.7 MILLION OF THEIR REMAINING BONDS INTO PHARMING SHARES AND CASH

BRIEF-Pharming Group Announces Significant Conversion Of Its Ordinary Convertible Bonds

* PHARMING ANNOUNCES SIGNIFICANT CONVERSION OF ITS ORDINARY CONVERTIBLE BONDS

BRIEF-Pharming Submits License Application to FDA for Ruconest

* PHARMING SUBMITS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION TO FDA FOR RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS

BRIEF-Pharming Group Q3 net result swings to profit of 7.5 million euros from Q2

* Q3 NET RESULT IMPROVED TO EUR 7.5 MILLION LOSS COMPARED WITH A LOSS OF EUR 24.5 MILLION IN Q2

BRIEF-Pharming Group announces positive data from paediatric clinical trial of Ruconest

* PHARMING ANNOUNCES POSITIVE DATA FROM PAEDIATRIC CLINICAL TRIAL WITH RUCONEST®

BRIEF-Pharming Group partners with Inceptua Medicines Access

* PHARMING GROUP N.V. AND HAEI INTERNATIONAL PATIENT ORGANIZATION ANNOUNCE PARTNERSHIP WITH INCEPTUA MEDICINES ACCESS FOR "HAEI GLOBAL ACCESS PROGRAM"

BRIEF-Pharming announces conclusion of FDA end of phase 2 interactions on Ruconest

* PHARMING ANNOUNCES CONCLUSION OF FDA END OF PHASE 2 INTERACTIONS ON RUCONEST FOR PROPHYLAXIS OF HAE

BRIEF-Pharming Group announces cashless warrant exercises and conversions of its ordinary bonds into shares

* ANNOUNCES CASHLESS WARRANT EXERCISES AND CONVERSIONS OF ITS ORDINARY BONDS INTO SHARES

BRIEF-Pharming Group H1 net loss widens to 30.2 million euros

* SAID ON THURSDAY THAT REVENUES FROM PRODUCT SALES FOR THE HALF YEAR INCREASED BY 617 PCT TO EUR 30.1 MILLION (HY 2016: EUR 4.2 MILLION)

BRIEF-Pharming announces publication of Ruconest prophylactic data in The Lancet

* PHARMING ANNOUNCES PUBLICATION OF RUCONEST PROPHYLACTIC DATA IN THE LANCET Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Pharming group announces completion of replacement of its 100 million dollars bridge finance

* ANNOUNCES THAT IT HAS COMPLETED REPLACEMENT OF ITS RECENTLY ANNOUNCED US$100 MILLION BRIDGE FINANCE WITH ORBIMED ADVISORS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up